INDUSTRY × Prostatic Neoplasms × 90 days × Clear all
NCT07623642 2026-06-03

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

GV20 Therapeutics

Phase 2 Not yet recruiting
227 enrolled
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled